Patient Data Shows Safe Switch from Genzyme to Shire Drug

Shire Human Genetic TherapiesDue to the temporary closing of Genzyme’s Allston plant last summer, MBBP client Shire’s new Gaucher Disease treatment VPRIV was fast-tracked and approved by the FDA.

Shire is now reporting data from a Phase 3 study which showed that when patients switched from Genzyme’s Cerezyme to Shire’s VPRIV, in the same dosage, several key health indicators remained the same.

For more information, please visit Shire.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s